These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33066983)

  • 21. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surgical treatment of pancreatic carcinoma: problems and recent advances].
    Yang YM; Zhao YP
    Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):401-403. PubMed ID: 27938571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.
    Nipp RD; Zanconato A; Zheng H; Ferrone CR; Lillemoe KD; Wo JY; Hong TS; Clark JW; Ryan DP; Fernández-Del Castillo C
    Pancreas; 2017 Feb; 46(2):183-189. PubMed ID: 27846142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 25. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The determinant factors of recurrence following resection for ductal pancreatic cancer.
    Barugola G; Falconi M; Bettini R; Boninsegna L; Casarotto A; Salvia R; Bassi C; Pederzoli P
    JOP; 2007 Jan; 8(1 Suppl):132-40. PubMed ID: 17228145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CRITICAL VIEWPOINT ON THE CURRENT APPROACH OF LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA].
    Van Daele D; Martinive P; Loly C; Polus M; Collignon J; Gast P; Louis E; Van Laethem JL
    Rev Med Liege; 2015 Nov; 70(11):540-5. PubMed ID: 26738264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discussion.
    J Am Coll Surg; 2016 Apr; 222(4):456-8. PubMed ID: 27016973
    [No Abstract]   [Full Text] [Related]  

  • 30. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
    [No Abstract]   [Full Text] [Related]  

  • 32. Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?
    Tamburrino D; Guarneri G; Partelli S; Crippa S; Falconi M; Capurso G
    Dig Liver Dis; 2021 Aug; 53(8):1065-1067. PubMed ID: 34011483
    [No Abstract]   [Full Text] [Related]  

  • 33. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis.
    Bradley A; Van Der Meer R
    PLoS One; 2019; 14(2):e0212805. PubMed ID: 30817807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
    Winner M; Goff SL; Chabot JA
    Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of surgical margins in pancreatic cancer.
    Ethun CG; Kooby DA
    J Surg Oncol; 2016 Mar; 113(3):283-8. PubMed ID: 26603829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.